Stocks and Investing
Stocks and Investing
Mon, May 6, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Nathan Rich Maintained (AMRX) at Strong Buy with Increased Target to $8 on, May 6th, 2024
Nathan Rich of Goldman Sachs, Maintained "Amneal Pharmaceuticals, Inc." (AMRX) at Strong Buy with Increased Target from $6.25 to $8 on, May 6th, 2024.
Nathan has made no other calls on AMRX in the last 4 months.
There are 2 other peers that have a rating on AMRX. Out of the 2 peers that are also analyzing AMRX, 0 agree with Nathan's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Nathan
- David Amsellem of "Piper Sandler" Maintained at Buy with Increased Target to $8 on, Thursday, March 21st, 2024
- Balaji Prasad of "Barclays" Maintained at Buy with Increased Target to $8 on, Monday, January 29th, 2024
Contributing Sources